Background <p>Sexual and gender diverse adolescents and young adults (SGDAYA) experience mental health disparities, yet few empirical investigations into the long-term impact of affirmative treatments on their well-being exist.</p> Methods <p>This study explored the longitudinal effects of a brief affirmative cognitive-behavioral therapy (CBT) group intervention (AFFIRM) on the depression and anxiety of SGDAYA (<i>N</i> = 202), as well as how pre-treatment and mid-intervention change mechanisms contributed to their improved mental health. Participants’ age ranged from 14 to 29 years old at baseline (<i>M</i> = 22.12, <i>SD</i> = 4.60). Data were collected at four time points (pre-test, post-test, 6 months, 1 year) and analyzed using hierarchical linear models.</p> Results <p>Participants reported significant improvements in anxiety and depression from baseline to 1-year follow-up as well as increased engagement coping, social support, hope, and improved stress appraisal. SGDAYA, who appraised stress as a threat and had less ability to envision a hopeful future (hope pathway) at baseline, reported greater improvements in depression and anxiety; additionally, those who used more disengagement coping strategies prior to AFFIRM reported more reduction in depression. Participants with the most significant long-term improvement in depression reported (a) greater increases in their resources to deal with stress, (b) more uptake of engagement coping, and (c) improved hope pathway.</p> Conclusions <p>This study suggests that an affirmative cognitive-behavioural group intervention designed for SGDAYA can have a long-term impact on their depression and anxiety and highlights the important role of engagement coping, social support, hope and cognitive appraisals on youth mental health.</p> Trial registration <p>AFFIRM was retrospectively registered as a clinical trial on March 24th, 2020 (identifier: NCT04318769).</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

LGBTQ + Affirmative CBT: a hierarchical linear model of longitudinal outcomes and mechanisms of change

  • Shelley L. Craig,
  • Vivian W. Y. Leung,
  • Jenny A. Hui,
  • Gio Iacono,
  • Rachael V. Pascoe,
  • Frank Dillon,
  • Ashley Austin,
  • Nelson Pang,
  • Cheryl Dobinson,
  • Ashley S. Brooks

摘要

Background

Sexual and gender diverse adolescents and young adults (SGDAYA) experience mental health disparities, yet few empirical investigations into the long-term impact of affirmative treatments on their well-being exist.

Methods

This study explored the longitudinal effects of a brief affirmative cognitive-behavioral therapy (CBT) group intervention (AFFIRM) on the depression and anxiety of SGDAYA (N = 202), as well as how pre-treatment and mid-intervention change mechanisms contributed to their improved mental health. Participants’ age ranged from 14 to 29 years old at baseline (M = 22.12, SD = 4.60). Data were collected at four time points (pre-test, post-test, 6 months, 1 year) and analyzed using hierarchical linear models.

Results

Participants reported significant improvements in anxiety and depression from baseline to 1-year follow-up as well as increased engagement coping, social support, hope, and improved stress appraisal. SGDAYA, who appraised stress as a threat and had less ability to envision a hopeful future (hope pathway) at baseline, reported greater improvements in depression and anxiety; additionally, those who used more disengagement coping strategies prior to AFFIRM reported more reduction in depression. Participants with the most significant long-term improvement in depression reported (a) greater increases in their resources to deal with stress, (b) more uptake of engagement coping, and (c) improved hope pathway.

Conclusions

This study suggests that an affirmative cognitive-behavioural group intervention designed for SGDAYA can have a long-term impact on their depression and anxiety and highlights the important role of engagement coping, social support, hope and cognitive appraisals on youth mental health.

Trial registration

AFFIRM was retrospectively registered as a clinical trial on March 24th, 2020 (identifier: NCT04318769).